Clinical epidemiology of carbapenem- resistant enterobacteriaceae in community hospitals: A case-case-control study

Annals of Pharmacotherapy

Volumn 47, Issue 9, 2013, Pages 1115-1121

  Lee, Grace C ^a,b   Lawson, Kenneth A ^b   Burgess, David S ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Beta lactam resistance; Carbapenem; Enterobacteriaceae; Epidemiology

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CEPHALOSPORIN; MACROLIDE; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; COMMUNITY HOSPITAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EXPOSURE; ENTEROBACTERIACEAE; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PATIENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

BETA-LACTAM RESISTANCE; CARBAPENEM; ENTEROBACTERIACEAE; EPIDEMIOLOGY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITALS, COMMUNITY; HUMANS; MALE; MIDDLE AGED; TEXAS;

EID: 84884486168     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013503120     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58:256-60.
2. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430-5. doi: 10.1001/archinte.165.12.1430
3. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenemresistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53: 60-7. doi: 10.1001/archinte.165.12.1430
4. Arnold RS, Thom KA, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ. Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. South Med J 2011;104:40-5. doi: 10.1097/SMJ.0b013e3181fd7d5a
5. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-106.
6. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 2009; 30:1180-5. doi: 10.1086/648451
7. Kwak YG, Choi SH, Choo EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005;11:165-9. doi: 10.1089/mdr.2005.11.165
8. Patel N, Harrington S, Dihmess A, et al. Clinical epidemiology of carbapenem-intermediate or-resistant Enterobacteriaceae. J Antimicrob Chemother 2011;66:1600-8. doi: 10.1093/jac/dkr156
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
10. Lesens O, Methlin C, Hansmann Y, et al. Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson Weighted Index of comorobidity. Infect Control Hosp Epidemiol 2003;24:890-6.
11. Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 2008;300:2911-3. doi: 10.1001/jama.2008.896
12. Kritsotakis EI, Tsioutis C, Roumbelaki M, Christidou A, Gikas A. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-β-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. J Antimicrob Chemother 2011;66:1383-91. doi: 10.1093/jac/dkr116
13. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009;30:666-71. doi: 10.1086/598244
14. Chang HJ, Hsu PC, Yang CC, et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study. J Microbiol Immunol Infect 2011;44:125-30. doi: 10.1016/j.jmii.2010.06.001
15. Wu D, Cai J, Liu J. Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae. South Med J 2011;104:106-10. doi: 10.1097/SMJ.0b013e318206063d
16. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007;60:1124-30. doi: 10.1093/jac/dkm356
17. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-casecontrol study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005;26:346-51. doi: 10.1086/502550
18. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-77. doi: 10.1086/510393
19. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53:1983-6. doi: 10.1128/AAC.01535-08
20. Marchaim D, Chopra T, Bhargava A, et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012;33:817-30. doi: 10.1086/666642